These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 34725212)
1. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. Zhu S; Ma AH; Zhu Z; Adib E; Rao T; Li N; Ni K; Chittepu VCSR; Prabhala R; Garisto Risco J; Kwiatkowski D; Mouw K; Sonpavde G; Cheng F; Pan CX J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725212 [TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203 [TBL] [Abstract][Full Text] [Related]
3. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. Han MG; Jang BS; Kang MH; Na D; Kim IA Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286 [TBL] [Abstract][Full Text] [Related]
4. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout. Zhen S; Lu J; Chen W; Zhao L; Li X Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042 [TBL] [Abstract][Full Text] [Related]
6. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233 [TBL] [Abstract][Full Text] [Related]
7. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130 [TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
10. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458 [TBL] [Abstract][Full Text] [Related]
11. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151 [TBL] [Abstract][Full Text] [Related]
12. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259 [TBL] [Abstract][Full Text] [Related]
13. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer. Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633 [TBL] [Abstract][Full Text] [Related]
14. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612 [TBL] [Abstract][Full Text] [Related]
15. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304 [TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251 [TBL] [Abstract][Full Text] [Related]
17. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
18. PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells. Xue X; Ye G; Zhang L; Zhu X; Liu Q; Rui G; Geng G; Lin Y; Chen X Int Immunopharmacol; 2024 Mar; 130():111747. PubMed ID: 38442576 [TBL] [Abstract][Full Text] [Related]
19. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949 [TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]